Clinical Trial Update: Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of elamipretide in subjects with primary mitochondrial disease from nuclear DNA mutations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Complex Deficiency
• Mitochondrial Diseases
• Mitochondrial Dna Deletion
• Mitochondrial Dna Depletion
• Mitochondrial Dna Mutation
• Mitochondrial Metabolism Defect
• Mitochondrial Myopathies
• Mitochondrial Pathology

Drugs mentioned

• Elamipretide (elamipretide)

Snippet

Sponsor: Stealth BioTherapeutics Inc. | Conditions: Mitochondrial Myopathies, Mitochondrial Pathology | Phase 3 | Status: COMPLETED